|
US7217788B2
(en)
|
1996-03-14 |
2007-05-15 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta polypeptides
|
|
US6541224B2
(en)
|
1996-03-14 |
2003-04-01 |
Human Genome Sciences, Inc. |
Tumor necrosis factor delta polypeptides
|
|
US6812327B1
(en)
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
AU757698C
(en)
|
1998-06-01 |
2004-04-08 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
PL211786B1
(pl)
|
1999-08-17 |
2012-06-29 |
Apoxis Sa |
Zastosowanie przeciwciała oraz polipeptydu
|
|
AU2048501A
(en)
*
|
2000-02-16 |
2001-08-27 |
Genentech Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US20040002068A1
(en)
*
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
DE60128216T2
(de)
*
|
2000-05-12 |
2008-01-10 |
Amgen Inc., Thousand Oaks |
Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001288301A1
(en)
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
CA2446734A1
(en)
|
2001-05-24 |
2002-11-28 |
Human Genome Sciences, Inc. |
Antibodies against tumor necrosis factor delta (april)
|
|
EA010594B1
(ru)
|
2001-05-24 |
2008-10-30 |
Займодженетикс, Инк. |
Слитые белки taci-иммуноглобулина
|
|
CA2453995A1
(en)
*
|
2001-08-03 |
2003-02-20 |
Genentech, Inc. |
Tacis and br3 polypeptides and uses thereof
|
|
US7494646B2
(en)
|
2001-09-06 |
2009-02-24 |
Agensys, Inc. |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
|
EP1516054B1
(de)
|
2002-02-10 |
2009-12-02 |
Topotarget Switzerland SA |
Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
|
|
US20080267965A1
(en)
*
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
|
US20050043516A1
(en)
*
|
2002-07-25 |
2005-02-24 |
Genentech, Inc. |
TACI antibodies and uses thereof
|
|
AU2004233164B2
(en)
|
2003-03-28 |
2009-10-08 |
Biogen Ma Inc. |
Truncated BAFF receptors
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
PT2272868E
(pt)
*
|
2003-06-05 |
2015-07-07 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
|
RU2006117324A
(ru)
|
2003-10-20 |
2007-12-10 |
Байоджен Айдек Ма Инк. (Us) |
Терапевтические режимы для антагонистов baff
|
|
NZ550816A
(en)
|
2004-04-22 |
2009-12-24 |
Agensys Inc |
Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
|
|
CN1786016B
(zh)
*
|
2004-12-09 |
2010-12-29 |
中国人民解放军军事医学科学院基础医学研究所 |
一种人工构建的生物活性分子及其制备方法
|
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
|
CA2596276A1
(en)
*
|
2005-01-28 |
2006-08-03 |
Biogen Idec Ma Inc. |
Use of baff to treat th2-mediated conditions
|
|
WO2007019573A2
(en)
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
|
CN101262876A
(zh)
|
2005-08-09 |
2008-09-10 |
酶遗传学股份有限公司 |
用taci-ig融合分子治疗b细胞恶性肿瘤的方法
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
US9726673B2
(en)
|
2005-11-23 |
2017-08-08 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
CN101489573B
(zh)
|
2006-05-15 |
2013-05-22 |
阿雷斯贸易股份有限公司 |
用TACI-Ig融合分子治疗自身免疫疾病的方法
|
|
AU2007308792B2
(en)
*
|
2006-10-27 |
2013-01-24 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
MD24Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
|
|
MD36Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
|
|
MD35Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
|
|
MD23Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
|
|
US20120201823A1
(en)
*
|
2009-10-14 |
2012-08-09 |
Schering Corporation |
April antagonists and methods of use
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
|
TW201425336A
(zh)
*
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
ES2731232T3
(es)
|
2013-03-15 |
2019-11-14 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
|
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
|
GB201317929D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
BR112016011004A2
(pt)
*
|
2013-11-19 |
2017-12-05 |
Regeneron Pharma |
animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
|
|
US20170247462A1
(en)
|
2014-07-03 |
2017-08-31 |
Oklahoma Medical Research Foundation |
Treatment of multiple sclerosis and neuromyelitis optica
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
AU2016302881B2
(en)
|
2015-08-03 |
2022-09-15 |
Bristol-Myers Squibb Company |
Monoclonal antibodies against BCMA
|
|
WO2017031104A1
(en)
|
2015-08-17 |
2017-02-23 |
Janssen Pharmaceutica Nv |
Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
|
|
AU2016353067B2
(en)
*
|
2015-11-13 |
2023-10-05 |
Sanford Research |
Anti-BCMA polypeptides and proteins
|
|
DK3380522T5
(da)
|
2015-11-25 |
2024-09-30 |
Visterra Inc |
Antistofmolekyler til april og anvendelser deraf
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
CN109641049B
(zh)
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
MY200988A
(en)
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
EP3535295A1
(en)
|
2016-11-02 |
2019-09-11 |
EngMab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
SG11202011306TA
(en)
|
2018-05-16 |
2020-12-30 |
Janssen Biotech Inc |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
BR112020024074A2
(pt)
|
2018-07-20 |
2021-02-17 |
Teneobio, Inc. |
anticorpos de cadeia pesada com ligação a cd19
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
BR112022001546A2
(pt)
|
2019-07-30 |
2022-03-22 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021222578A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
PH12022553023A1
(en)
|
2020-05-11 |
2024-03-04 |
Janssen Biotech Inc |
Methods for treating multiple myeloma
|
|
CN115996748A
(zh)
*
|
2020-05-29 |
2023-04-21 |
奇努克医疗公司 |
用APRIL结合抗体治疗IgA肾病的方法
|
|
PE20230464A1
(es)
|
2020-06-30 |
2023-03-14 |
Teneobio Inc |
Union de anticuerpos multiespecificos a bcma
|
|
IL305144A
(en)
|
2021-02-16 |
2023-10-01 |
Janssen Pharmaceutica Nv |
Trispecific antibodies targeting BCMA, GPRC5D and CD3
|
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔｃｒに結合する多機能性分子およびその使用
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
EP4384201A4
(en)
|
2021-08-11 |
2025-07-30 |
Akso Biopharmaceutical Inc |
METHODS FOR REDUCING THE PRODUCTION OF IGA, IGM AND/OR IGG IMMUNOGLOBULINS USING SBCMA VARIANTS AND THEIR FC FUSION PROTEINS
|
|
WO2023081705A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
CN121263449A
(zh)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
Cd19/cd38多特异性抗体
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025174963A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026061495A1
(zh)
*
|
2024-09-20 |
2026-03-26 |
长春金赛药业有限责任公司 |
一种阻断BAFF、APRIL作用其受体的Fc融合蛋白
|